Want to see DMRA full AI Analyst Report?
Top Page
Damora Therapeutics
(NASDAQ:DMRA)
Select Model
Select Model
Rating:57Neutral
Price Target:
$30.00
▲(4.09% Upside)
Action:Reiterated
Date:07/21/26
The score is held back primarily by weak financial performance (no revenue, large and volatile losses, and ongoing cash burn), partially offset by a strong technical uptrend and low leverage on the balance sheet. Valuation support is limited because earnings are negative and there is no dividend.
Positive Factors
Very low leverage
Minimal debt lowers fixed financial obligations and reduces insolvency risk while the company funds development. This gives management more flexibility than a highly leveraged biotech, although it does not eliminate the need for future capital.
Negative Factors
Pre-revenue business model
The absence of revenue confirms that Damora remains dependent on development progress rather than an established commercial franchise. Without product sales, future funding, milestones, and investor support remain central to sustaining operations.
Read all positive and negative factors
Positive Factors
Negative Factors
Very low leverage
Minimal debt lowers fixed financial obligations and reduces insolvency risk while the company funds development. This gives management more flexibility than a highly leveraged biotech, although it does not eliminate the need for future capital.
Read all positive factors
Damora Therapeutics (DMRA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.89B
Dividend YieldN/A
Average Volume (3M)793.64K
Price to Earnings (P/E)―
Beta (1Y)0.08
Revenue GrowthN/A
EPS Growth-850.33%
CountryUS
Employees7
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-122.42
Shares Outstanding61,735,520
10 Day Avg. Volume469,145
30 Day Avg. Volume793,645
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.13
Price to Sales (P/S)0.00
P/FCF Ratio-4.66
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$43.33Price Target Upside50.36% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-2
Revenue Forecast (FY)N/A
Damora Therapeutics Business Overview & Revenue Model
Company Description
Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company’s lead product includes DMR-001, a investigational monoclonal antibody therapy that tar...
Damora Therapeutics Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
62
Positive
Cash Flow
28
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -79.00K | 0.00 | -181.00K | -830.00K | -490.00K | -441.00K |
| EBITDA | -263.34M | -209.75M | -21.22M | -37.52M | -61.13M | -51.31M |
| Net Income | -259.69M | -209.84M | -21.44M | -38.35M | -61.62M | -51.75M |
Balance Sheet | ||||||
| Total Assets | 543.64M | 260.53M | 17.13M | 38.23M | 73.19M | 122.22M |
| Cash, Cash Equivalents and Short-Term Investments | 540.51M | 257.62M | 14.18M | 33.15M | 60.22M | 100.19M |
| Total Debt | 0.00 | 68.00K | 1.43M | 249.00K | 804.00K | 847.00K |
| Total Liabilities | 27.58M | 20.15M | 2.66M | 5.90M | 11.44M | 4.99M |
| Stockholders Equity | 516.06M | 240.38M | 14.47M | 32.33M | 61.75M | 117.22M |
Cash Flow | ||||||
| Free Cash Flow | -41.90M | -6.73M | -18.62M | -36.91M | -43.13M | -52.53M |
| Operating Cash Flow | -41.90M | -6.73M | -18.62M | -36.91M | -42.93M | -52.31M |
| Investing Cash Flow | -17.37M | -17.37M | 11.65M | 22.33M | 12.38M | -48.05M |
| Financing Cash Flow | 592.27M | 266.84M | 0.00 | 2.88M | 507.00K | 0.00 |
Damora Therapeutics Technical Analysis
Positive
28.82
Price Trends
28.89
Positive
26.62
Positive
25.90
Positive
Market Momentum
0.48
Positive
52.78
Neutral
24.27
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DMRA, the sentiment is Positive. The current price of 28.82 is below the 20-day moving average (MA) of 30.46, below the 50-day MA of 28.89, and above the 200-day MA of 25.90, indicating a bullish trend. The MACD of 0.48 indicates Positive momentum. The RSI at 52.78 is Neutral, neither overbought nor oversold. The STOCH value of 24.27 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DMRA.
Damora Therapeutics Risk Analysis
Damora Therapeutics disclosed 71 risk factors in its most recent earnings report. Damora Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Damora Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
63 Neutral | $3.74B | -11.44 | -40.51% | ― | 34.52% | 41.20% | |
58 Neutral | $1.70B | -64.69 | 442.91% | ― | 107.73% | 82.33% | |
57 Neutral | $1.89B | -0.23 | -82.56% | ― | ― | -850.33% | |
56 Neutral | $2.10B | -9.41 | -59.36% | ― | -86.20% | -476.63% | |
52 Neutral | $2.07B | -14.00 | -72.07% | ― | -69.78% | -106.07% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $2.02B | -14.46 | -26.51% | ― | ― | ― |
* Healthcare Sector Average
DMRA
Damora Therapeutics
29.00
25.82
811.95%
IOVA
Iovance Biotherapeutics
8.01
5.78
259.19%
ANAB
AnaptysBio
56.28
42.73
315.32%
ZYME
Zymeworks
28.27
13.46
90.88%
STOK
Stoke Therapeutics
31.62
11.86
60.02%
GENB
Generate Biomedicines, Inc.
15.33
2.68
21.19%
Damora Therapeutics Corporate Events
Business Operations and StrategyRegulatory Filings and ComplianceShareholder Meetings
Damora Therapeutics Completes Cayman Islands Redomestication
Neutral
Jul 20, 2026
On February 9, 2026, Damora Therapeutics’ stockholders approved a plan to redomesticate the company from Delaware to the Cayman Islands, a move that became effective on July 16, 2026. Under this plan of conversion, the company filed the nece...
Executive/Board ChangesShareholder Meetings
Damora Therapeutics Announces Results of 2026 Annual Meeting
Neutral
Jun 17, 2026
Damora Therapeutics, Inc. held its 2026 Annual Meeting of Stockholders on June 17, 2026, at which shareholders elected Michael Landsittel and Cameron Turtle, D.Phil, as Class III directors to serve until the 2029 annual meeting, and approved on an...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.